PubRank

P Vermersch

Author PubWeight™ 104.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992 4.16
2 The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999 3.49
3 Unusual MR findings of the brain stem in arterial hypertension. AJNR Am J Neuroradiol 2000 3.47
4 A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993 3.16
5 Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005 2.53
6 The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001 2.15
7 Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010 1.75
8 Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol 1995 1.67
9 Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001 1.62
10 Neuromyelitis optica and pregnancy. Neurology 2012 1.49
11 Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007 1.45
12 Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis. J Neurol 2000 1.42
13 Long-term follow-up of neurosarcoidosis. Neurology 2001 1.36
14 Association of multiple sclerosis with ILT6 deficiency. Genes Immun 2005 1.34
15 Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002 1.33
16 Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol 2010 1.20
17 Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain 2001 1.17
18 Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 2009 1.15
19 [Severe Guillain-Barré syndrome and pregnancy: two cases with rapid improvement post-partum]. Rev Neurol (Paris) 2006 1.09
20 Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 1991 1.07
21 Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett 1997 1.06
22 Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp Neurol 2007 1.05
23 Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol 1996 1.04
24 Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005 1.00
25 Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004 1.00
26 Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993 1.00
27 Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charcot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. Neuromuscul Disord 2004 0.99
28 Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003 0.97
29 Visual rating of hippocampal atrophy: correlation with volumetry. J Neurol Neurosurg Psychiatry 1994 0.95
30 [Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase]. Rev Neurol (Paris) 2006 0.94
31 Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004 0.94
32 Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett 1996 0.92
33 Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 2005 0.90
34 Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 2009 0.90
35 Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010 0.90
36 Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. J Neurol Neurosurg Psychiatry 1998 0.89
37 Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001 0.88
38 Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 2008 0.86
39 Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. J Neurol 2001 0.86
40 [BCcogSEP: a French test battery evaluating cognitive functions in multiple sclerosis]. Rev Neurol (Paris) 2004 0.86
41 One-and-a-half syndrome in pontine infarcts: MRI correlates. Neuroradiology 1999 0.86
42 [Cortical blindness associated with Guillain-Barre syndrome: a complication of dysautonomia?]. Rev Neurol (Paris) 2005 0.86
43 Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004 0.86
44 Hemifacial spasm due to pontine infarction. J Neurol Neurosurg Psychiatry 1991 0.86
45 Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 2004 0.85
46 [Neuropsychiatric systemic lupus erythematosus (1st part). Cases definitions and diagnosis and treatment of central nervous system and psychiatric manifestations of systemic lupus erythematosus]. Rev Med Interne 2012 0.85
47 High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler 2011 0.85
48 Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol 2010 0.85
49 [Inaugural psychotic events in multiple sclerosis?]. Rev Neurol (Paris) 2009 0.84
50 [Neuromeningeal tuberculosis: the contribution of genetic amplification to diagnosis]. Rev Neurol (Paris) 2004 0.84
51 Cerebrovascular symptomatic involvement in sarcoidosis. Acta Neurol Belg 2010 0.83
52 Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011 0.83
53 Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol 2003 0.83
54 Relapsing inflammatory optic neuritis: is it neuromyelitis optica? Neurology 2008 0.83
55 Sensorineural deafness in X-linked Charcot-Marie-Tooth disease with connexin 32 mutation (R142Q) Neurology 1999 0.83
56 Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. Clin Neurophysiol 2003 0.83
57 Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J Neurochem 1997 0.83
58 Accuracy of postcontrast 3D turbo spin-echo MR sequence for the detection of enhanced inflammatory lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol 2013 0.82
59 IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J Neuroimmunol 2001 0.82
60 Unusual ocular motor findings in multiple sclerosis. J Neurol Sci 2006 0.82
61 Acute aphasia in multiple sclerosis: A multicenter study of 22 patients. Neurology 2004 0.81
62 Creutzfeldt-Jakob disease: neurophysiologic visual impairments. Neurology 1998 0.81
63 [Neurological manifestations in Sjögren syndrome]. Rev Med Interne 2005 0.81
64 The first European family with tibial muscular dystrophy outside the Finnish population. Neurology 1998 0.81
65 Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. Mult Scler 2005 0.81
66 Pupillary disturbances in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2001 0.81
67 CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol 2004 0.81
68 Severe hypoglycorrhachia after subarachnoid hemorrhage. Two cases with spontaneous recovery in adults. Acta Neurol Belg 1987 0.80
69 Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997 0.80
70 [Infectious myelopathies: clinical, serological, and prognostic patterns]. Rev Neurol (Paris) 2004 0.80
71 [Late onset multiple sclerosis]. Rev Neurol (Paris) 2002 0.80
72 Man-in-the-barrel syndrome caused by a pontine lesion. Neurology 2005 0.79
73 Guillain-Barré syndrome resembling brainstem death in a patient with brain injury. J Neurol 2001 0.79
74 [High prevalence of restless legs syndrome in multiple sclerosis]. Rev Neurol (Paris) 2008 0.79
75 Novel epsilon subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome. J Neurol Neurosurg Psychiatry 2009 0.78
76 Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport 1999 0.78
77 [Strongyloides stercoralis myelitis]. Rev Neurol (Paris) 1995 0.78
78 [Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients]. Rev Med Interne 1998 0.78
79 Molecular analysis of endogenous retrovirus HRES-1: identification of frameshift mutations in region encoding putative 28-kDa autoantigen. Biochem Biophys Res Commun 2001 0.78
80 Long-term outcome of acute and subacute myelopathies. J Neurol 2009 0.78
81 [Bilateral phrenic nerve paralysis, dysautonomia and restrictive cardiomyopathy in a case of POEMS syndrome]. Rev Neurol (Paris) 2002 0.78
82 A new case of autosomal dominant myotonia associated with the V1589M missense mutation in the muscle sodium channel gene and its phenotypic classification. Neuromuscul Disord 2006 0.78
83 Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler 2013 0.78
84 Clinical and mutational spectrum of limb-girdle muscular dystrophy type 2I in 11 French patients. J Neurol Neurosurg Psychiatry 2009 0.78
85 No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. Mult Scler 2011 0.78
86 [Clinical manifestations and therapeutic approach in neurosarcoidosis]. Rev Neurol (Paris) 2000 0.77
87 Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2000 0.77
88 [Hemiballismus. Hemichorea. Striatal infarction]. Rev Neurol (Paris) 1990 0.77
89 [Tubular aggregate congenital myopathy associated with neuromuscular block]. Rev Neurol (Paris) 2001 0.76
90 One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler 2005 0.76
91 The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler 2008 0.76
92 [Presentation of Niemann-Pick type C disease with psychiatric disturbance in an adult]. Rev Neurol (Paris) 2005 0.76
93 [Normal cerebral aging: study of glial reaction]. C R Acad Sci III 1994 0.76
94 Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. Neurology 2006 0.76
95 [Myelopathy - Sjogren's syndrome association: analysis of clinical and radiological findings and clinical course]. Rev Neurol (Paris) 2001 0.76
96 Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol 2003 0.76
97 Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. Neuroreport 1995 0.76
98 [Phenotypic aspects of FKRP-linked muscular dystrophy type 2I in a series of eleven patients]. Rev Neurol (Paris) 2007 0.76
99 Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis. Mult Scler 2009 0.76
100 Atypical form of non-Langerhans histiocytosis with disseminated brain and leptomeningeal lesions. J Neurol Neurosurg Psychiatry 2000 0.75
101 [Hypertrophy of the biceps surae after post-radiation lumbar radiculopathy]. Rev Neurol (Paris) 2003 0.75
102 A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2013 0.75
103 [Spinal cord disorders and systemic diseases]. Rev Med Interne 2000 0.75
104 High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol 2015 0.75
105 [Collet-Sicard syndrome disclosing periarteritis nodosa]. Rev Neurol (Paris) 1998 0.75
106 Pulse-triggered DTI sequence with reduced FOV and coronal acquisition at 3T for the assessment of the cervical spinal cord in patients with myelitis. AJNR Am J Neuroradiol 2012 0.75
107 [Pure subacute pandysautonomia: an assessment of treatment with intravenous polyvalent immunoglobulins]. Rev Neurol (Paris) 2004 0.75
108 A family with a novel frameshift mutation in the PMP22 gene (c.433_434insC) causing a phenotype of hereditary neuropathy with liability to pressure palsies. Neuromuscul Disord 2005 0.75
109 [Subcutaneous apomorphine in major motor oscillations of parkinsonian patients]. Presse Med 1992 0.75
110 Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003 0.75
111 Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 2011 0.75
112 [Neurological manifestations in Sjögren syndrome]. Rev Med Interne 2010 0.75
113 [Is leuko-araiosis in Alzheimer's disease, in Parkinson's disease and in healthy elderly persons the result of Wallerian degeneration?]. Acta Neurol Belg 1990 0.75
114 [Paraplegia episodes revealing tuberculous myelitis]. Rev Neurol (Paris) 2000 0.75
115 Alpha-fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome. Neurology 2003 0.75
116 [Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus]. Rev Med Interne 2012 0.75
117 [Magnetic resonance imaging of the facial nerve in a case of Melkerson-Rosenthal syndrome]. Rev Neurol (Paris) 1998 0.75
118 [Regressive leukoencephalopathy in chronic brucellosis]. Rev Neurol (Paris) 1997 0.75
119 Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. Mult Scler 2007 0.75
120 [Tibial muscular dystrophy. A rare form of distal myopathy]. Rev Neurol (Paris) 1999 0.75
121 Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome. J Neuroimmunol 2002 0.75
122 Some clinical aspects of late onset parkinsonism. Clin Neurol Neurosurg 1992 0.75
123 [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. Rev Neurol (Paris) 2012 0.75
124 [Candida albicans meningoencephalomyeloradiculitis]. Rev Neurol (Paris) 2002 0.75
125 [Heterogeneity of Alzheimer's disease]. Rev Neurol (Paris) 1993 0.75
126 [Singular, systemic, self-reactive IgG patterns related to age: relationship with cerebral malaria susceptibility in exposed subjects residing in an endemic area in Abidjan, Côte-d'Ivoire]. Bull Soc Pathol Exot 2012 0.75
127 [Dropped head syndrome: report of two cases]. Rev Med Interne 2005 0.75
128 [Adrenoleukomyeloneuropathy in an adult]. Rev Neurol (Paris) 1993 0.75
129 [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment]. Rev Neurol (Paris) 2007 0.75
130 [Primary progressive forms of multiple sclerosis: application of the new diagnostic criteria in French]. Rev Neurol (Paris) 2002 0.75
131 [Bilateral third cranial nerve palsy triggered by an acute relapse of multiple sclerosis]. Rev Neurol (Paris) 2005 0.75
132 Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann Neurol 2000 0.75
133 Brain MRI in late-onset multiple sclerosis. Eur J Neurol 2005 0.75
134 Possible revelation of latent myasthenia gravis by labetalol chlorhydrate. Acta Clin Belg 1987 0.75
135 [Sarcoidosis and progressive multifocal leukoencephalopathy]. Rev Neurol (Paris) 2001 0.75
136 [Guillain-Barré syndrome with hallucinations and onirism: an underestimated association]. Rev Neurol (Paris) 2004 0.75
137 [Adenovirus myelitis and Epstein-Barr myelitis: two unusual viral causes with similar presentations]. Rev Neurol (Paris) 2000 0.75
138 [Fulminant multiple sclerosis]. Rev Neurol (Paris) 2000 0.75
139 Severe oedema after subcutaneous apomorphine in Parkinson's disease. Lancet 1989 0.75
140 Congenital myopathy with central cores and fingerprint bodies in association with malignant hyperthermia susceptibility. Neuromuscul Disord 2001 0.75
141 [Subcortical dementia: is a revision of the concept necessary?]. Rev Neurol (Paris) 1995 0.75
142 Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. Acta Neurol Scand 2000 0.75
143 [Contribution of morphological imaging in the diagnosis of dementia. I--Alzheimer disease]. Rev Med Interne 1994 0.75
144 [Morphological imaging in the diagnosis of dementia. II. Vascular dementia]. Rev Med Interne 1995 0.75
145 Cardiac repolarization abnormalities in multiple sclerosis: spinal cord MRI correlates. Muscle Nerve 2000 0.75
146 A localized postoperative cervical syrinx revealed by orthostatic hypotension. Eur Neurol 1998 0.75
147 [Kjellin syndrome]. Rev Neurol (Paris) 2001 0.75
148 [Sensory disorders in multiple sclerosis (before optic neuropathy)]. Rev Neurol (Paris) 2001 0.75
149 [Neurologic emergencies]. J Neuroradiol 2004 0.75
150 [Polymyositis revealing a Sjogren's syndrome]. Rev Neurol (Paris) 2009 0.75
151 [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study]. Rev Neurol (Paris) 2008 0.75
152 [Conclusion]. Rev Neurol (Paris) 2009 0.75
153 [Retroperitoneal fibrosis after treatment with bromocriptine]. Presse Med 1989 0.75
154 [Late onset of type I familial amyloid neuropathy: results of biopsy from accessory salivary glands]. Rev Neurol (Paris) 1999 0.75
155 [Polymyositis and cranial neuropathy]. Rev Neurol (Paris) 2007 0.75
156 [Between the infection and the vaccine, one must choose]. Rev Med Interne 1998 0.75
157 [Multiple sclerosis with sensory disturbances and hyperhidrosis of the hand]. Rev Neurol (Paris) 2004 0.75
158 [Treatment of progressive multiple sclerosis with cyclophosphamide]. Rev Neurol (Paris) 2002 0.75
159 [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]. Rev Neurol (Paris) 2008 0.75
160 [Chronic polyradiculoneuritis disclosing sarcoidosis]. Rev Neurol (Paris) 2002 0.75
161 [Hearing loss in multiple sclerosis: clinical, electrophysiologic and radiological study]. Rev Neurol (Paris) 2001 0.75
162 [Editorial. Spasticity in multiple sclerosis]. Rev Neurol (Paris) 2012 0.75
163 [Editorial: multiple sclerosis]. Rev Neurol (Paris) 2009 0.75
164 [Cavitary lesions in multiple sclerosis: multicenter study on twenty patients]. Rev Neurol (Paris) 2013 0.75
165 Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. Autoimmunity 1997 0.75
166 [Spinal cord magnetic resonance imaging in multiple sclerosis: importance of determining degree of atrophy as a marker of disease course]. Rev Neurol (Paris) 2000 0.75
167 [Epstein-Barr meningoencephaloradiculitis in a immunocompetent woman]. Rev Neurol (Paris) 2002 0.75
168 [Ataxic neuropathy associated with disialosylated antibodies: description of new clinical and biochemical forms]. Rev Neurol (Paris) 2004 0.75
169 Diltiazem for tardive dyskinesia. Lancet 1988 0.75